For personal use only

Market Announcement

11 March 2026

Immutep Limited (ASX: IMM) – Suspension from Quotation

The securities of Immutep Limited ('IMM') will be suspended from quotation immediately under Listing Rule 17.2 at the request of IMM, pending the release of an announcement by IMM.

Unless ASX decides otherwise, the securities will remain suspended until the earlier of:

- the end of the period stated in IMM's request for voluntary suspension; or
- the release of the announcement to the market.

IMM's request for voluntary suspension is attached below for the information of the market.

Issued by

ASX Compliance

immutep
Empowering the Immune System

For personal use only

11 March 2026

ASX Compliance Pty Ltd
Exchange Centre
20 Bridge Street
Sydney NSW 2000

By email: tradinghaltssydney@asx.com.au

Dear Sirs,

Immutep Limited (ASX: IMM) – Request for voluntary suspension

On 6 March 2026, Immutep Limited ACN 009 237 889 (**Immutep**) requested that an immediate trading halt be granted by ASX in respect of its ordinary shares pending an announcement by Immutep regarding the outcome of the pre-specified interim futility analysis for the TACTI-004 (KEYNOTE-F91) Phase III trial evaluating its lead candidate, eftilagimod alfa (**Futility Analysis**). Pursuant to ASX Listing Rule 17.2, Immutep now requests that ASX grant a voluntary suspension in the trading of its ordinary shares effective immediately.

Immutep requests the suspension pending the announcement regarding the outcome of the Futility Analysis.

In accordance with ASX Listing Rule 17.2, Immutep provides the following information:

(a) **Reason for voluntary suspension**: the voluntary suspension is requested as Immutep is not yet in a position to make the announcement referred to in its trading halt request of 6 March 2026 and to ensure that trading does not take place in an uninformed market.

(b) **Duration of the voluntary suspension**: Immutep requests that the voluntary suspension continue until the earlier of such time as it makes an announcement to the market in relation to the Futility Analysis or the commencement of trading on Friday, 13 March 2026.

(c) **Termination of the voluntary suspension**: Immutep anticipates that the voluntary suspension will cease upon it announcing the outcome of the Futility Analysis.

(d) **No reason**: Immutep is not aware of any reason why the voluntary suspension should not be granted by ASX.

(e) **Further information**: Immutep is not aware of any further information which needs to be disclosed to the market at the time of seeking the voluntary suspension.

Yours faithfully

Deanne Miller
COO, General Counsel & Company Secretary
Immutep Limited

This document is authorised for release by the CEO of Immutep Limited.